Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 82

Similar articles for PubMed (Select 20498710)

1.

Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG.

van den Boorn JG, Konijnenberg D, Tjin EP, Picavet DI, Meeuwenoord NJ, Filippov DV, van der Veen JP, Bos JD, Melief CJ, Luiten RM.

PLoS One. 2010 May 13;5(5):e10626. doi: 10.1371/journal.pone.0010626.

2.

Topical CpG enhances the response of murine malignant melanoma to dacarbazine.

Najar HM, Dutz JP.

J Invest Dermatol. 2008 Sep;128(9):2204-10. doi: 10.1038/jid.2008.59. Epub 2008 Mar 27.

3.
4.

Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.

Broomfield SA, van der Most RG, Prosser AC, Mahendran S, Tovey MG, Smyth MJ, Robinson BW, Currie AJ.

J Immunol. 2009 May 1;182(9):5217-24. doi: 10.4049/jimmunol.0803826.

6.

Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions.

Redondo P, del Olmo J, López-Diaz de Cerio A, Inoges S, Marquina M, Melero I, Bendandi M.

J Invest Dermatol. 2007 Jul;127(7):1673-80. Epub 2007 Mar 22.

7.

The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice.

Ma F, Zhang J, Zhang J, Zhang C.

Cell Mol Immunol. 2010 Sep;7(5):381-8. doi: 10.1038/cmi.2010.30. Epub 2010 Jun 14.

8.

Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma.

Green DS, Dalgleish AG, Belonwu N, Fischer MD, Bodman-Smith MD.

Br J Dermatol. 2008 Sep;159(3):606-14. doi: 10.1111/j.1365-2133.2008.08709.x. Epub 2008 Jul 4.

PMID:
18616776
9.

Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants.

Morera Y, Bequet-Romero M, Ayala M, Lamdán H, Agger EM, Andersen P, Gavilondo JV.

Angiogenesis. 2008;11(4):381-93. doi: 10.1007/s10456-008-9121-5. Epub 2008 Nov 26.

PMID:
19034678
10.

Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients.

Molenkamp BG, Sluijter BJ, van Leeuwen PA, Santegoets SJ, Meijer S, Wijnands PG, Haanen JB, van den Eertwegh AJ, Scheper RJ, de Gruijl TD.

Clin Cancer Res. 2008 Jul 15;14(14):4532-42. doi: 10.1158/1078-0432.CCR-07-4711.

11.

NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides.

Kawarada Y, Ganss R, Garbi N, Sacher T, Arnold B, Hämmerling GJ.

J Immunol. 2001 Nov 1;167(9):5247-53.

12.

Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine.

Johnston D, Bystryn JC.

Vaccine. 2006 Mar 10;24(11):1958-65. Epub 2005 Nov 8.

PMID:
16310898
13.

CpG-Oligodeoxynucleotides activate tyrosinase-related protein 2-specific T lymphocytes but do not lead to a protective tumor-specific memory response.

Sfondrini L, Besusso D, Bronte V, Macino B, Rossini A, Colombo MP, Ménard S, Balsari A.

Cancer Immunol Immunother. 2004 Aug;53(8):697-704. Epub 2004 Mar 18.

PMID:
15034674
14.

Reduced tumorigenicity of B16-F10 mouse melanoma cells transfected with mycobacterial antigen 85A.

Tarrant JP, Walsh MJ, Blanchard MC, Lee TD, Hoskin DW, Giacomantonio CA.

Int J Oncol. 2004 Dec;25(6):1693-9.

PMID:
15547707
15.

Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination.

Chuang CM, Monie A, Hung CF, Wu TC.

J Biomed Sci. 2010 Apr 28;17:32. doi: 10.1186/1423-0127-17-32.

16.

Anti-metastatic activity induced by the in vivo activation of purified protein derivative (PPD)-recognizing Th1 type CD4+ T cells.

Shinomiya Y, Harada M, Kurosawa S, Okamoto T, Terao H, Matsuzaki G, Shirakusa T, Nomoto K.

Immunobiology. 1995 Aug;193(5):439-55.

PMID:
8522359
17.

Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy.

van den Boorn JG, Picavet DI, van Swieten PF, van Veen HA, Konijnenberg D, van Veelen PA, van Capel T, Jong EC, Reits EA, Drijfhout JW, Bos JD, Melief CJ, Luiten RM.

J Invest Dermatol. 2011 Jun;131(6):1240-51. doi: 10.1038/jid.2011.16. Epub 2011 Feb 17.

18.

Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model.

Molavi O, Ma Z, Hamdy S, Lai R, Lavasanifar A, Samuel J.

Immunol Cell Biol. 2008 Aug-Sep;86(6):506-14. doi: 10.1038/icb.2008.27. Epub 2008 Apr 8.

PMID:
18392040
19.

Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes.

Perricone MA, Smith KA, Claussen KA, Plog MS, Hempel DM, Roberts BL, St George JA, Kaplan JM.

J Immunother. 2004 Jul-Aug;27(4):273-81.

PMID:
15235388
20.

Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells.

Sabel MS, Arora A, Su G, Mathiowitz E, Reineke JJ, Chang AE.

Surgery. 2007 Nov;142(5):749-60.

PMID:
17981196
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk